ChromaDex Co. (NASDAQ:CDXC) Sees Significant Growth in Short Interest

ChromaDex Co. (NASDAQ:CDXC) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 2,070,000 shares, a growth of 6.7% from the December 15th total of 1,940,000 shares. Currently, 4.3% of the shares of the company are sold short. Based on an average daily volume of 1,270,000 shares, the short-interest ratio is currently 1.6 days.

Insider Buying and Selling

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the transaction, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 9.64% of the stock is owned by company insiders.

Hedge Funds Weigh In On ChromaDex

Large investors have recently bought and sold shares of the business. USA Financial Formulas purchased a new stake in shares of ChromaDex in the fourth quarter valued at approximately $25,000. The Manufacturers Life Insurance Company purchased a new stake in ChromaDex in the 2nd quarter worth $31,000. Merriman Wealth Management LLC acquired a new position in ChromaDex during the second quarter worth $32,000. FMR LLC purchased a new position in ChromaDex during the third quarter valued at $55,000. Finally, SG Americas Securities LLC acquired a new stake in shares of ChromaDex in the third quarter valued at about $61,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

ChromaDex Trading Up 5.1 %

ChromaDex stock opened at $5.94 on Tuesday. The firm has a market cap of $453.72 million, a PE ratio of 594.59 and a beta of 2.21. The stock’s 50 day simple moving average is $6.32 and its two-hundred day simple moving average is $4.49. ChromaDex has a 12 month low of $1.36 and a 12 month high of $7.97.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The company had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same quarter last year, the business earned ($0.01) earnings per share. On average, equities research analysts forecast that ChromaDex will post 0.04 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. HC Wainwright upped their target price on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 4th. StockNews.com downgraded shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 15th. Finally, Roth Mkm boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.